

International Childhood Cancer Cohort Consortium (14C)

Terry Dwyer*

Martha Linet** Jean Golding***

Ora Paltiel**** Jorn Olsen*****

Camilla Stoltenberg***** Somdat Mahabir**

Zdenko Herceg***** Gabriella Tikellis*

* *Murdoch Childrens Research Institute, Australia*

** *National Cancer Institute, NIH USA*

*** *United Kingdom: ALSPAC*

**** *Jerusalem*

***** *Denmark*

***** *Norwegian MoBa*

***** *IARC*

Data on human subjects is essential for gaining an understanding of the environmental causes of childhood cancer and adds great value to the genetic research

Case-control studies of the kind involved in the CLIC consortium are a central component of this work

because they allow us to conduct studies with substantial power and focused measurement of exposures – cost-effectively

However in research on childhood cancer additional evidence from prospective cohort studies is highly desirable

- to address concerns regarding recall bias and
- to permit collection of biological specimens prior to disease onset

Environmental chemicals

Infections in childhood


Birth weight

In childhood cancer, cohort studies have been difficult to mount

because they need to be very large

Number of cases of cancer occurring in a cohort of 100,000 children followed from 0-14

For all cancers n = 242



Number needed to study leukemia (Acute Lymphoblastic Leukemia & Acute Myeloid Leukemia)


Percentage of subjects exposed	Minimum risk detectable	Power %	Number Required
5	1.5	80	1180059
15	1.5	80	446633
30	1.5	80	277781

Garcia-Closas M, Lubin JH. *Am J Epidemiol.* 1999

Age-adjusted SEER cancer incidence rates USA 1975-2002

No study of children in the world involves the necessary 1 million subjects.

However, since 1990 a number of countries have commenced large infant/child cohort studies



Norwegian Mother & Child Cohort Study - Norway

105,422

ALSPAC - UK

14,541

Danish National Birth Cohort - Denmark

96,840

EFESE - France

20,000

Sino-US CPBDDP - China

245,000


National Children's Study - USA

100,000


Tasmanian Infant Health Survey - Australia

10,627

	Biological samples for genotyping etc	Birth weight and birth order	Folate	Environmental exposures	Childhood infections
<i>National Children's Study</i>	✓	✓	✓	✓	✓
<i>Norwegian Mother and Child Study</i>	✓	✓	✓	✓	✓
<i>Danish National Birth Cohort</i>	✓	✓	✓	✓	✓
<i>Avon Longitudinal Study of Parents and Children</i>	✓	✓	✓	✓	✓
<i>Tasmanian Infant Health Survey</i>	✓	✓	✓	✓	✓
<i>Jerusalem Perinatal Study</i>	X	✓	X	✓	✓
<i>Collaborative Perinatal Project</i>	✓	✓	?	✓	✓



Data on 380,000 subjects has now been received at the IDCC.



Pooled analysis on 190,000 subjects: birth weight and child cancer

POOLED DATA FROM TIHS, ALSPAC, CPP AND JPS 2: Case-cohort analysis (Sept 8th 2011)			
Subcohort = 2323	ALL CHILDHOOD CANCER (N=130) and Birth weight (groups) HR (95%CI)	ANY LEUKEMIA (N=33) and Birth weight (groups) HR (95%CI)	ALL (N=25) and Birth weight (groups) HR (95%CI)
UNADJUSTED			
<2500g	1.22 (0.67-2.22)	0.82 (0.19-3.44)	0.50 (0.07-3.75)
2500-3999	Ref	Ref	Ref
4000+	1.63 (0.92-2.91)	2.50 (0.96-6.50) p=0.06	1.85 (0.55-6.19)
ADJ for GEST AGE			
<2500g	0.72(0.35-1.48)	0.72 (0.12-4.25)	0.39 (0.05-2.98)
2500-3999	Ref	Ref	Ref
4000+	1.70 (0.90-3.20)	3.16 (1.16-8.63) p=0.025	2.33 (0.68-7.99)
ADJ for GEST AGE, SEX			
<2500g	0.74 (0.36-1.52)	0.72 (0.12-4.33)	0.41 (0.05-3.12)
2500-3999	Ref	Ref	Ref
4000+	1.61 (0.85-3.06)	3.04 (1.10-8.38) p=0.03	2.12 (0.64-7.06)
ADJ for GEST AGE, MAT Diabetes*			
<2500g	0.62 (0.20-1.92)	0.59 (0.05-6.95)	too small numbers
2500-3999	Ref	Ref	Ref
4000+	2.25 (1.10-4.61) p=0.026	3.42 (1.12-10.45) p=0.03	3.37 (1.03-10.97) p=0.04
*n=6			
ADJ for GEST AGE, MAT AGE			
<2500g	1.18 (0.57-2.42)	0.73 (0.11-4.76)	0.39 (0.05-3.21)
2500-3999	Ref	Ref	Ref
4000+	1.91 (0.98-3.73) p=0.057	2.86 (0.99-8.28) p=0.052	2.02 (0.55-7.43)
ADJ for GEST AGE, PAT AGE			
<2500g	0.63 (0.27-1.46)	0.64 (0.05-7.50)	too small numbers
2500-3999	Ref	Ref	Ref
4000+	1.40 (0.70-2.77)	2.89 (1.01-8.25) p=0.048	2.10 (0.55-7.48)

Healthier Kids. Healthier Future.

Maternal prenatal smoking

TIHS

- One month postnatal

Q31: How much did you smoke during your pregnancy?

Cigarettes Smoked	A 1 st Trimester (0-13 weeks)	B 2 nd Trimester (14-27 weeks)	C 3 rd Trimester (28-40 weeks)
Nil			
1-10/day			
11-20/day			
21-40/day			
41+/day			

Old_T	
Category score	Meaning
0	None
1	1-10
2	11-20
3	21-40
4	41+

New	
Category score	Meaning
0	None
1	1-10
2	11-20
3	21+

ALSPAC

- 18 weeks gestation

G3. f) Did you smoke regularly at any of the following times in the last 9 months?

First 3 months of pregnancy, last 2 weeks.

- No Yes, cigarettes Yes, other

- 32 weeks gestation

E3 How many cigarettes per day are you yourself smoking at the moment?.....cigarettes

Old_A	
Category score	Meaning
0	None
1	1-4
2	5-9
3	10-14
4	15-19
5	20-24
6	25-29
7	30+

New	
Category score*	Meaning
0	None
1	1-10
1	
2	11-20
2	
3	21+
3	
3	

* New score=0 if type of smoking **not** cigarettes

I4C cohorts: Biospecimens

	TIHS	ALSPAC	BDSS-China	DNBC	MoBa	CPP
Biospecimens – Mother Blood	√	√	X	√	√	X
Biospecimens - Child						
Cord blood	(1,000)	√	X	√	√	√
Guthrie cards	Guthrie (n~520)		X	X	PKU	X

NCPS Package

International Childhood
Cancer Cohort Consortium
(I4C)

New Cohort Protocol
Support Package (NCPS)

Developed by:

Gabriella Tikellis* (gabriella.tikellis@mcri.edu.au)

Terry Dwyer (terry.dwyer@mcri.edu.au)

Anne-Louise Ponsonby (anne-louise.ponsonby@mcri.edu.au)

* Contact person

- The NCPS package comprises of 2 main parts:
 - 1) An Excel Workbook
 - 2) A Word document.